Skip to main content

Table 3 Concentration of platelet-derived growth factors of patients with chronic renal disease hemodialysed (before and after HD A, HD B), peritoneal dialysis (PD), conservative treatment (CT), before and after kidney transplantation (TE, TE A) and in the control group (NK) (mean ± OS, median – lower and upper quartile)

From: Effect of renal replacement therapy on selected arachidonic acid derivatives concentration

Concentration of arachidonic acid derivatives
Groups
TXB2 [ng/mL] 5-HETE [ng/mL] 12-HETE [ng/mL] 15-HETE [ng/mL]
HD A 34,6 ± 9 284,2 ± 428,4 3,0 ± 0,4 18,1 ± 8,7
36,9 (29,8; 41,8) 76,8 (1,34; 1465) 2,83 (2,5; 4) 17,0 (4,4; 40,1)
HD B 34,3 ± 10,5 304,8 ± 516,2 3,1 ± 0,6 42,2 ± 14,8
38,5 (30,7; 40,9) 65,92 (1,11; 1580) 3,0 (1,3; 4,9) 44,9 (18,3; 76,1)
PD 28,3 ± 15,2 530,0 ± 553,3 3,1 ± 2,1 36,3 ± 13,8
29,8 (17,8; 37,4) 199,4 (11,6; 1511) 3,0 (0,1; 13,2) 38,5 (11,6; 68,6)
CT 34,2 ± 8,0 318,7 ± 366,0 3,0 ± 0,8 33,7 ± 14,0
35,6 (26,9; 42,3) 151,4 (8,4; 1333,3) 3,2 (0,1; 4,1) 28,8 (13,4; 65,9)
TE 36,7 ± 42,9 525,6 ± 358,0 3,7 ± 1,9 19,5 ± 10,2
23,16 (14,18; 38,7) 622,6 (25,7; 1219,0) 2,8 (1,8; 8,8) 15,8 (1,9; 43,6)
TE A 27,9 ± 8,8 409,8 ± 377,1 2,8 ± 0,8 34,4 ± 16,3
26,7 (20,9; 34,7) 265,4 (13,6; 1157) 2,7 (0,1; 4,8) 35,4 (7,2; 73,0)
NK 19,6 ± 15 838,1 ± 497,8 3,3 ± 1,0 22,2 ± 17,8
18,3 (10,0; 25,5) 792,0 (21,9; 1933,8) 3,1 (1,5; 6,9) 19,4 (0,2; 89,2)
P 0,010 < 0,001 NS < 0,001